Symbiotix Biotherapies, Inc. is developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. The company’s lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases.

T2 Biosystems T2 Biosystems (NASDAQ: TTOO) is a biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics.

Verinata Health, Inc. (acquired by Illumina, Inc.) developed non-invasive tests for the early identification of fetal chromosomal abnormalities.

XTuit Pharmaceuticals is pursuing novel approaches to improving cancer therapy by targeting the tumor microenvironment.

ZELTIQ™(NASDAQ: ZLTQ) is medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat. The device is cleared by the FDA in the United States for various applications related to skin cooling during dermatologic treatments, with a pending application for non-invasive body fat reduction. Based on a method to kill…

Selecta Biosciences, Inc.is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. Selecta’s synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.

BIND Biosciences (NASDAQ: BIND) is a biopharmaceutical company founded to develop therapeutic targeted nanoparticles to produce best in class drugs. Initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics.

Blend is developing novel cancer therapeutics designed to overcome efficacy barriers for improved targeting of cancer. Blend’s innovative medicines leverage tumor biology to gain therapeutic advantage in unique ways. With their Pentarin platform, they create miniaturized biologic drug conjugate (mBDC) incorporated in polymeric nanoparticles that are designed to reach and penetrate the solid tumor and…

Cytrellis Biosystems Inc. is a clinical stage medical device company developing a new class of medical devices with an unprecedented ability to reverse age related changes in skin and restore youthful beauty. Their products will address a longstanding need to provide doctors and their patients with a safe, effective and non-surgical means to eliminate unwanted…

Exosome Diagnostics, is developing body fluid-based cancer diagnostics using its exosome-based technology for disease stratification and patient response monitoring. Exosome Diagnostics’ technology allows for minimally invasive testing of cancer specific genes from standard blood and urine samples.

Fate Therapeutics (NASDAq: FATE) is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators, small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative…

GeneInsight is an IT platform developed to streamlines interpretation and management of vast amounts of data clinical genomic data, offering a key step towards the promise of personalized medicine and better patient care.